Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer

NCT05609370 is registered in ClinicalTrials.gov with BeiGene as lead sponsor.

NCT NCT05609370
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05609370 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine as Maintenance Therapy in Patients With Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer
Lead sponsor
BeiGene
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
January 29, 2023
Completion date
December 31, 2026
Enrollment
113 (actual)
Sites
64

Conditions

As the registry lists them; a condition with its own page is linked.

unresectable or metastatic microsatellite stable/mismatch repair proficient colorectal cancer